Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:35:34.542Z.
Calculation as of: 2026-10-06T15:35:34.542Z.
Quote observation: 2026-10-06T15:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$796.03M
EV/FCF Ratio
N/A
TTM Avg
402.12x
3Y Avg
246.51x
5Y Avg
209.59x
Market Cap
$795.58M
EV/FCF Ratio
28.84x
TTM Avg
18.09x
3Y Avg
34.83x
5Y Avg
61.33x
Market Cap
$787.65M
EV/FCF Ratio
N/A
TTM Avg
3.79x
3Y Avg
3.79x
5Y Avg
6.31x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $807.61M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.31M | 4.73x | 6.37x | 8.04x | 13.91x |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 4.50x | 4.50x | 4.50x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $796.03M | N/A | 402.12x | 246.51x | 209.59x |
| AdaptHealth Corp. (AHCO)vs › | $795.58M | 28.84x | 18.09x | 34.83x | 61.33x |
| Geron Corporation (GERN)vs › | $790.35M | N/A | 58.32x | 58.32x | 58.32x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $787.65M | N/A | 3.79x | 3.79x | 6.31x |
| Attovia Therapeutics, Inc. (ATTO)vs › | $780.99M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $834.69M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $841.20M | N/A | 241.82x | 97.19x | 51.67x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
